Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced that Dr. Philip Brown, senior vice president of clinical development at Lexicon, delivered an oral presentation at the annual meeting of the European Neuroendocrine Tumor Society (ENETS). The presentation summarized Phase 1 clinical trial results for [...]